Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 22
Filter
1.
Can J Surg ; 64(1): E66-E68, 2021 02 03.
Article in English | MEDLINE | ID: mdl-33533582

ABSTRACT

Pressure to reduce health care costs, limited hospital bed availability as well as improvements in surgical techniques and perioperative care motivated many health care centres to implement short-stay protocols for patients undergoing hip or knee arthroplasty. To improve patient outcomes and maintain care safety, we strongly believe the best way to implement a successful outpatient program would be to embrace the principles of Enhanced Recovery After Surgery (ERAS), and to improve patient recovery to a level such that the patient could leave the hospital sooner. Enhanced Recovery Canada and the Canadian Patient Safety Institute support the development of ERAS pathways for orthopedic procedures. The goal is to provide patients, health care providers and leaders with helpful tools and resources to effectively implement and sustain ERAS protocols. Reducing the rate of adverse events while reducing the length of hospital stays to less than 24 hours is a winning situation for everyone.


Subject(s)
Arthroplasty, Replacement, Hip , Arthroplasty, Replacement, Knee , Enhanced Recovery After Surgery , Length of Stay/statistics & numerical data , Clinical Protocols , Humans
2.
Healthc Q ; 22(SP): 72-81, 2020 Feb.
Article in English | MEDLINE | ID: mdl-32049617

ABSTRACT

Patients undergoing surgery today experience longer hospital stays and more complications because evidence-based practices in the areas of nutrition, activity, opioid-sparing analgesia, hydration and overall best practices are not consistently applied or used. There is also emerging evidence that supporting patients and families to become engaged in their perioperative care improves outcomes. Enhanced Recovery After Surgery (ERAS) helps patients be more prepared for surgery and recover more quickly by bringing patients, healthcare providers and health systems together and creating tools and resources that are based on the most up-to-date evidence. The goal of Enhanced Recovery Canada is to support the uptake of these best practices across Canada, improving patient outcomes and experiences.


Subject(s)
Enhanced Recovery After Surgery , Perioperative Care/methods , Postoperative Complications/prevention & control , Canada , Critical Pathways , Evidence-Based Practice , Humans , Patient Safety
3.
Can J Surg ; 63(1): E19-E20, 2020 01 16.
Article in English | MEDLINE | ID: mdl-31944637

ABSTRACT

Summary: Enhanced Recovery After Surgery (ERAS) is a model of care that was introduced in the late 1990s by a group of surgeons in Europe. The model consists of a number of evidence-based principles that support better outcomes for surgical patients, including improved patient experience, reduced length of stay in hospital, decreased complication rates and fewer hospital readmissions. A number of Canadian surgical care teams have already adopted ERAS principles and have reported positive outcomes. Arising from the Canadian Patient Safety Institute's Integrated Patient Safety Action Plan for Surgical Care Safety, and with support from numerous partner organizations from across the country, Enhanced Recovery Canada is leading the drive to improve surgical safety across the country and help disseminate these ERAS principles. We discuss the development of a multidisciplinary clinical pathway for elective colorectal surgery to help guide Canadian clinicians.


Subject(s)
Colorectal Surgery/standards , Critical Pathways/standards , Enhanced Recovery After Surgery/standards , Patient Care Team/standards , Patient Safety/standards , Canada , Evidence-Based Medicine/standards , Humans
4.
BMJ Qual Saf ; 28(1): 32-38, 2019 01.
Article in English | MEDLINE | ID: mdl-29844230

ABSTRACT

BACKGROUND: Prevention of healthcare-associated urinary tract infection (UTI) has been the focus of a national effort, yet appropriate indications for insertion and removal of urinary catheters (UC) among surgical patients remain poorly defined. METHODS: We developed and implemented a standardised approach to perioperative UC use to reduce postsurgical UTI including standard criteria for catheter insertion, training of staff to insert UC using sterile technique and standardised removal in the operating room and surgical unit using a nurse-initiated medical directive. We performed an interrupted time series analysis up to 2 years following intervention. The primary outcome was the proportion of patients who developed postsurgical UTI within 30 days as measured by the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP). Process measures included monthly UC insertions, removals in the operating room and UC days per patient-days on surgical units. RESULTS: At baseline, 22.5% of patients were catheterised for surgery, none were removed in the operating room and catheter-days per patient-days were 17.4% on surgical units. Following implementation of intervention, monthly catheter removal in the operating room immediately increased (range 12.2%-30.0%) while monthly UC insertion decreased more slowly before being sustained below baseline for 12 months (range 8.4%-15.6%). Monthly catheter-days per patient-days decreased to 8.3% immediately following intervention with a sustained shift below the mean in the final 8 months. Postsurgical UTI decreased from 2.5% (95% CI 2.0-3.1%) to 1.4% (95% CI 1.1-1.9; p=0.002) during the intervention period. CONCLUSIONS: Standardised perioperative UC practices resulted in measurable improvement in postsurgical UTI. These appropriateness criteria for perioperative UC use among a broad range of surgical services could inform best practices for hospitals participating in ACS NSQIP.


Subject(s)
Catheter-Related Infections/prevention & control , Perioperative Care , Quality Improvement , Urinary Catheterization/standards , Catheter-Related Infections/epidemiology , Female , Humans , Male , Middle Aged , Ontario/epidemiology , Population Surveillance
5.
Can J Anaesth ; 66(1): 75-108, 2019 01.
Article in English | MEDLINE | ID: mdl-30560409

ABSTRACT

OVERVIEW: The Guidelines to the Practice of Anesthesia Revised Edition 2019 (the Guidelines) were prepared by the Canadian Anesthesiologists' Society (CAS), which reserves the right to determine their publication and distribution. The Guidelines are subject to revision and updated versions are published annually. The Guidelines to the Practice of Anesthesia Revised Edition 2019 supersedes all previously published versions of this document. Although the CAS encourages Canadian anesthesiologists to adhere to its practice guidelines to ensure high-quality patient care, the CAS cannot guarantee any specific patient outcome. Anesthesiologists should exercise their own professional judgement in determining the proper course of action for any patient's circumstances. The CAS assumes no responsibility or liability for any error or omission arising from the use of any information contained in its Guidelines to the Practice of Anesthesia.


Subject(s)
Anesthesiology/standards , Canada , Humans , Patient Care/standards , Quality of Health Care/standards , Societies, Medical
7.
Injury ; 49(1): 117-123, 2018 Jan.
Article in English | MEDLINE | ID: mdl-29183635

ABSTRACT

BACKGROUND: Hypothermia (<36°C) exacerbates trauma-induced coagulopathy and worsens morbidity and mortality among severely injured trauma patients; there is a paucity of published data describing how well trauma centres adhere to standards regarding measurement of temperature, and best practices for preventing and treating hypothermia. METHODS: We completed a retrospective quality audit of all severely injured trauma patients (Injury Severity Score (ISS≥20)) who had urgent surgery at Sunnybrook Health Sciences Centre (SHSC) between 2010 and 2014. Information regarding temperature monitoring was evaluated over the course of the initial resuscitation and admission. Independent risk factors for in-hospital mortality were elucidated through a multivariable regression analysis. RESULTS: Out of a total of 4492 trauma patients, 495 were severely-injured and went to the operating room (OPR) after being treated in the trauma bay (TB) at SHSC between 2010 and 2014. The majority of the patients were male (n=384, 77.6%) and had a blunt mechanism of injury (n=391, 79.0%). The median ISS score was 29 (interquartile range (IQR) 26, 35). Eighty-nine (17.9%) patients died; 26 (5.2%) of these patients died intra-operatively. Less than one fifth of patients (n=82,16.6%) received a temperature measurement during pre-hospital transport phase. Upon arrival to the TB, almost two-thirds (n=301, 60.8%) of patients had their temperature recorded and a similar proportion (n=175, 58.1%) of those patients were hypothermic (<36°C). In the OPR, close to 80% (n=389, 78.6%) of patients had their temperature measured on both arrival; almost 60% (n=223, 57.3%) were hypothermic on arrival. Almost all patients had their temperature measured upon arrival to the ICU or specialized ward (n=450, 98.3%). Warming initiatives were documented in only 36 (7.3%) patients in the TB, yet documented in almost all patients in OR (n=464, 93.7%). An increased risk of in-hospital mortality was correlated with not taking a temperature measurement in the TB (Odds Ratio (OR) 2.86 (95% Confidence Interval (CI) [1.64-4.99]) or OPR (OR 4.66 (95% CI [2.50-8.69]). CONCLUSIONS: A majority of severely injured trauma patients are hypothermic well into the perioperative period after initial admission. An absence of having temperature measurement during initial hospitalization is associated with increased in-hospital mortality amongst this patient group. Quality improvement initiatives should aim to strive for ongoing temperature measurement as a key performance indicator and early prevention and treatment of hypothermia during initial resuscitation.


Subject(s)
Blood Coagulation Disorders/prevention & control , Critical Illness/therapy , Hypothermia, Induced , Trauma Centers , Wounds, Nonpenetrating/therapy , Wounds, Penetrating/therapy , Adult , Blood Coagulation Disorders/etiology , Blood Coagulation Disorders/physiopathology , Canada , Clinical Audit , Female , Humans , Injury Severity Score , Male , Middle Aged , Odds Ratio , Quality of Health Care , Retrospective Studies , Risk Factors , Treatment Outcome , Wounds, Nonpenetrating/complications , Wounds, Nonpenetrating/physiopathology , Wounds, Penetrating/complications , Wounds, Penetrating/physiopathology
8.
Can J Anaesth ; 65(1): 76-104, 2018 01.
Article in English | MEDLINE | ID: mdl-29243160

ABSTRACT

OVERVIEW: The Guidelines to the Practice of Anesthesia Revised Edition 2018 (the Guidelines) were prepared by the Canadian Anesthesiologists' Society (CAS), which reserves the right to determine their publication and distribution. The Guidelines are subject to revision and updated versions are published annually. The Guidelines to the Practice of Anesthesia Revised Edition 2018 supersedes all previously published versions of this document. Although the CAS encourages Canadian anesthesiologists to adhere to its practice guidelines to ensure high-quality patient care, the CAS cannot guarantee any specific patient outcome. Anesthesiologists should exercise their own professional judgement in determining the proper course of action for any patient's circumstances. The CAS assumes no responsibility or liability for any error or omission arising from the use of any information contained in its Guidelines to the Practice of Anesthesia.


Subject(s)
Anesthesia/standards , Anesthesiology/standards , Patient Care/standards , Anesthesia/methods , Anesthesiologists/organization & administration , Anesthesiologists/standards , Anesthesiology/methods , Canada , Guideline Adherence , Humans , Quality of Health Care
9.
Can J Anaesth ; 64(1): 65-91, 2017 Jan.
Article in English | MEDLINE | ID: mdl-27837405

ABSTRACT

OVERVIEW: The Guidelines to the Practice of Anesthesia Revised Edition 2017 (the guidelines) were prepared by the Canadian Anesthesiologists' Society (CAS), which reserves the right to determine their publication and distribution. Because the guidelines are subject to revision, updated versions are published annually. The Guidelines to the Practice of Anesthesia Revised Edition 2017 supersedes all previously published versions of this document. Although the CAS encourages Canadian anesthesiologists to adhere to its practice guidelines to ensure high-quality patient care, the society cannot guarantee any specific patient outcome. Each anesthesiologist should exercise his or her own professional judgement in determining the proper course of action for any patient's circumstances. The CAS assumes no responsibility or liability for any error or omission arising from the use of any information contained in its Guidelines to the Practice of Anesthesia.


Subject(s)
Anesthesia/standards , Anesthesiology/standards , Anesthesiology/instrumentation , Canada , Catheterization, Central Venous , Humans , Monitoring, Intraoperative , Patient Care , Preanesthetic Medication , Preoperative Care , Ultrasonography, Interventional
10.
Crit Care ; 20(1): 107, 2016 Apr 20.
Article in English | MEDLINE | ID: mdl-27095272

ABSTRACT

Hypothermia is present in up to two-thirds of patients with severe injury, although it is often disregarded during the initial resuscitation. Studies have revealed that hypothermia is associated with mortality in a large percentage of trauma cases when the patient's temperature is below 32 °C. Risk factors include the severity of injury, wet clothing, low transport unit temperature, use of anesthesia, and prolonged surgery. Fortunately, associated coagulation disorders have been shown to completely resolve with aggressive warming. Selected passive and active warming techniques can be applied in damage control resuscitation. While treatment guidelines exist for acidosis and bleeding, there is no evidence-based approach to managing hypothermia in trauma patients. We synthesized a goal-directed algorithm for warming the severely injured patient that can be directly incorporated into current Advanced Trauma Life Support guidelines. This involves the early use of warming blankets and removal of wet clothing in the prehospital phase followed by aggressive rewarming on arrival at the hospital if the patient's injuries require damage control therapy. Future research in hypothermia management should concentrate on applying this treatment algorithm and should evaluate its influence on patient outcomes. This treatment strategy may help to reduce blood loss and improve morbidity and mortality in this population of patients.


Subject(s)
Hypothermia/etiology , Transfusion Reaction , Wounds and Injuries/complications , Blood Transfusion/mortality , Disease Management , Humans , Hypothermia/mortality , Resuscitation/adverse effects , Rewarming/methods , Wounds and Injuries/mortality , Wounds and Injuries/physiopathology
11.
J Am Coll Surg ; 215(6): 850-7, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23164141

ABSTRACT

BACKGROUND: Surgical site infection (SSI) adversely affects patient outcomes and health care costs, so prevention of SSI has garnered much attention worldwide. Surgical site infection is recognized as an important quality indicator of patient care and safety. The purpose of this study was to use qualitative research methods to evaluate staff perceptions of the utility and impact of individualized audit and feedback (AF) data on SSI-related process metrics for their individual practice, as well as on overall communication and teamwork as they relate to SSI prevention. STUDY DESIGN: This study was performed in a tertiary care center, based on patients treated in the colorectal and hepatic-pancreatic-biliary surgical oncology services. Eighteen clinicians were interviewed. Analysis of interviews via comparative analysis techniques and coding strategies were used to identify themes. RESULTS: The most important finding of this study was that although nearly all participants believed that the individualized AF model was useful in effecting individual practice change as well as improving awareness and accountability around individual roles in preventing SSIs, it was not seen as a means to enable the multidisciplinary teamwork required for sustainable practice changes. Moreover, such teamwork requires a team leader. CONCLUSIONS: Provision of individualized AF data had a significant impact on promoting individual practice change. Despite this, we concluded that practice change is a shared responsibility, requiring a team leader. So, AF had little bearing on establishing a necessary multidisciplinary team approach to SSI prevention, to create more effective and sustainable practice change among an entire team.


Subject(s)
Clinical Audit/methods , Operating Rooms/standards , Qualitative Research , Surgical Wound Infection/prevention & control , Humans , Ontario
14.
Med Hypotheses ; 76(4): 489-91, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21183285

ABSTRACT

Translating advances in the laboratory into sound clinical practice presents a series of formidable conceptual and technical challenges. One of them is our inability to maintain large grafts of living cells upon transfer from in vitro conditions into the host in vivo. This is due mainly to diffusion limitations within the grafting material. We embrace the well-known hypothesis of the "Diamond Concept" in bone tissue regeneration, which includes four key factors. Based on the understanding of basic elements of tissue engineering constructs, prefabrication and conditioning techniques and the nano-vascularisation of the scaffold, we furthermore hypothesize that combinations of cells, solid multipolymeric scaffold as the "core element" working as the extracellular matrix (ECM), growth factors and nano-vascularisation setting may eventually generate a large "ready-to-use"in vitro/in vivo graft. We are confident and think that growth factors will help in the construction of a step-by-step organisation of the bone tissue engineering construct (BTEC). A medical device, named in vitro/in vivo Bone Bioreactor Tissue Engineering Construct (IV2B2TEC), is proposed to fulfil the hypothesis. Soon, we hope to test the above hypothesis on a non-union bone defect in an animal model. This novel strategy will likely open new options for reconstructing extended bone defects and facilitate clinical translation of bone tissue engineering. As compared with conventional reconstructive methods, the strategy has four key advantages and might prove to be a novel armamentarium for clinicians in regenerative medicine.


Subject(s)
Bioreactors , Bone Regeneration , Bone Transplantation , Tissue Engineering/instrumentation , Humans , Intercellular Signaling Peptides and Proteins/pharmacology , Intercellular Signaling Peptides and Proteins/physiology , Neovascularization, Physiologic , Stem Cells/drug effects , Stem Cells/physiology , Tissue Scaffolds , Transplants
15.
Arch Oral Biol ; 55(9): 689-701, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20627196

ABSTRACT

OBJECTIVE: The aim of this study was to investigate the in vitro osteogenic activity of EGF in association with bone morphogenetic proteins BMP2 and BMP7. METHODS: SaOS-2 (osteoblast-like cell line from human osteosarcoma) were cultured in the presence of EGF and BMPs for various culture periods to assess (a) cell proliferation by MTT assay, (b) Runx2, alkaline phosphatase (ALP) and osteocalcin (OC) mRNA expression using quantitative RT-PCR and ELISA, and (c) bone tissue mineralization using Alizarin Red staining. RESULTS: EGF alone was able to stimulate osteoblast growth in a time-dependent manner. When mixed with BMP2, BMP7, and their combination, EGF greatly promoted osteoblast growth, compared to the BMP- and EGF-stimulated cells, suggesting a possible synergistic effect between EGF and BMPs on osteoblast growth. Stimulation with EGF, EGF/BMP2, and EGF/BMP2/BMP7 for 7 days upregulated Runx2 mRNA expression by the osteoblasts. EGF downregulated ALP mRNA expression, which was recovered when the BMP2/BMP7 combination was added to the osteoblast culture. Tested on OC mRNA expression, EGF had no effect and inhibited the enhancing effect of BMP2 and BMP7 on osteocalcin expression. The bone mineralization assay showed that EGF reduced both the number and size of the bone nodules. This reducing effect was observable even in the presence of BMP2 and BMP7. CONCLUSION: This study demonstrated that EGF may act in the early phase to promote osteoblast growth and specific marker expression rather than the late phase involving cell differentiation/mineralization.


Subject(s)
Bone Morphogenetic Protein 2/physiology , Bone Morphogenetic Protein 7/physiology , Epidermal Growth Factor/physiology , Osteoblasts/cytology , Osteocalcin/biosynthesis , Osteogenesis/drug effects , Alkaline Phosphatase/biosynthesis , Analysis of Variance , Biomarkers/metabolism , Bone Morphogenetic Protein 2/pharmacology , Bone Morphogenetic Protein 7/pharmacology , Calcification, Physiologic/drug effects , Cell Line, Tumor , Cell Proliferation/drug effects , Core Binding Factor Alpha 1 Subunit/biosynthesis , Enzyme-Linked Immunosorbent Assay , Epidermal Growth Factor/pharmacology , Gene Expression Regulation , Humans , Osteoblasts/drug effects , Osteoblasts/metabolism , Osteogenesis/physiology , RNA/analysis , Reverse Transcriptase Polymerase Chain Reaction , Statistics, Nonparametric , Up-Regulation
16.
Interact Cardiovasc Thorac Surg ; 10(5): 732-6, 2010 May.
Article in English | MEDLINE | ID: mdl-20061339

ABSTRACT

Patients who received clopidogrel prior to coronary bypass surgery are at increased risk for bleeding that must be balanced with risk of ongoing ischemia if coronary artery bypass grafting is delayed. This study aimed to evaluate the impact of clopidogrel on mortality and major bleeding in patients undergoing urgent coronary bypass surgery. We reviewed 451 consecutive patients who underwent urgent isolated coronary bypass surgery; 262 had not received clopidogrel, whereas 189 received clopidogrel < or = 5 days preoperative. The primary endpoint was in-hospital death, massive transfusion or massive blood loss. Patient characteristics were almost similar between groups. There was no difference in in-hospital death or massive bleeding indices between groups (clopidogrel: 7% vs. no clopidogrel: 6%, P = 0.9). No difference was observed even after adjusting for the date of stopping clopidogrel preoperatively. Multivariate regression analysis showed that clopidogrel or the duration it was stopped preoperatively, did not predict adverse outcomes. Significant independent predictors included preoperative renal dysfunction, hemoglobin level and peripheral vascular disease. clopidogrel, or the time it was stopped prior to surgery, was not a risk factor for in-hospital death, massive bleeding, or other poor early outcomes in patients undergoing urgent coronary artery bypass surgery.


Subject(s)
Coronary Artery Bypass/methods , Coronary Stenosis/surgery , Postoperative Hemorrhage/chemically induced , Postoperative Hemorrhage/mortality , Ticlopidine/analogs & derivatives , Analysis of Variance , Clopidogrel , Cohort Studies , Coronary Angiography/methods , Coronary Artery Bypass/adverse effects , Coronary Stenosis/diagnostic imaging , Coronary Stenosis/mortality , Dose-Response Relationship, Drug , Drug Administration Schedule , Emergency Treatment/methods , Female , Follow-Up Studies , Hospital Mortality/trends , Humans , Logistic Models , Male , Multivariate Analysis , Postoperative Complications/chemically induced , Postoperative Complications/mortality , Postoperative Complications/physiopathology , Postoperative Hemorrhage/physiopathology , Reference Values , Retrospective Studies , Risk Assessment , Severity of Illness Index , Statistics, Nonparametric , Survival Rate , Ticlopidine/adverse effects , Ticlopidine/therapeutic use
18.
Indian J Dent Res ; 20(2): 141-9, 2009.
Article in English | MEDLINE | ID: mdl-19553712

ABSTRACT

BACKGROUND: Porphyromonas gingivalis, an important periodontal pathogen, is closely associated with inflammatory alveolar bone resorption. This bacterium exerts its pathogenic effect indirectly through multiple virulence factors, such as lipopolysaccharides, fimbriae, and proteases. Another possible pathogenic path may be through a direct interaction with the host's soft and hard tissues (e.g., alveolar bone), which could lead to periodontitis. AIMS AND OBJECTIVES: The aim of the present study was to investigate the direct effect of live and heat-inactivated P gingivalis on bone resorption, using an in vitro osteoblast culture model. RESULTS: Optical microscopy and 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide MTT assay revealed that live P gingivalis induced osteoblast detachment and reduced their proliferation. This effect was specific to live bacteria and was dependent on their concentration. Live P gingivalis increased IL-6 mRNA expression and protein production and downregulated RANKL and OPG mRNA expression. The effect of live P gingivalis on bone resorption was strengthened by an increase in MMP-9 expression and its activity. This increase was accompanied by an increase in TIMP-1 and TIMP-2 mRNA expression and protein production by osteoblasts infected with live P gingivalis. CONCLUSION: Overall, the results suggest that direct contact of P gingivalis with osteoblasts induces bone resorption through an inflammatory pathway that involves IL-6, RANKL/OPG, and MMP-9/TIMPs.


Subject(s)
Interleukin-6/immunology , Matrix Metalloproteinase 9/immunology , Osteoblasts/microbiology , Osteoprotegerin/immunology , Porphyromonas gingivalis/immunology , RANK Ligand/immunology , Tissue Inhibitor of Metalloproteinases/immunology , Bone Resorption/immunology , Bone Resorption/microbiology , Cell Adhesion/immunology , Cell Line, Tumor , Cell Proliferation , Coloring Agents , Down-Regulation , Host-Pathogen Interactions/immunology , Humans , Matrix Metalloproteinase 2/immunology , Osteoblasts/immunology , Tetrazolium Salts , Thiazoles , Tissue Inhibitor of Metalloproteinase-1/immunology , Tissue Inhibitor of Metalloproteinase-2/immunology
19.
Circulation ; 119(4): 495-502, 2009 Feb 03.
Article in English | MEDLINE | ID: mdl-19153273

ABSTRACT

BACKGROUND: Acute kidney injury (AKI) after cardiac surgery is a major health issue. Lacking effective therapies, risk factor modification may offer a means of preventing this complication. The objective of the present study was to identify and determine the prognostic importance of such risk factors. METHODS AND RESULTS: Data from a multicenter cohort of 3500 adult patients who underwent cardiac surgery at 7 hospitals during 2004 were analyzed (using multivariable logistic regression modeling) to determine the independent relationships between 3 thresholds of AKI (>25%, >50%, and >75% decrease in estimated glomerular filtration rate within 1 week of surgery or need for postoperative dialysis) with death rates, as well as to identify modifiable risk factors for AKI. The 3 thresholds of AKI occurred in 24% (n=829), 7% (n=228), and 3% (n=119) of the cohort, respectively. All 3 thresholds were independently associated with a >4-fold increase in the odds of death and could be predicted with several perioperative variables, including preoperative intra-aortic balloon pump use, urgent surgery, and prolonged cardiopulmonary bypass. In particular, 3 potentially modifiable variables were also independently and strongly associated with AKI. These were preoperative anemia, perioperative red blood cell transfusions, and surgical reexploration. CONCLUSIONS: AKI after cardiac surgery is highly prevalent and prognostically important. Therapies aimed at mitigating preoperative anemia, perioperative red blood cell transfusions, and surgical reexploration may offer protection against this complication.


Subject(s)
Cardiac Surgical Procedures/adverse effects , Cardiac Surgical Procedures/statistics & numerical data , Cardiovascular Diseases/surgery , Kidney Diseases/etiology , Kidney Diseases/mortality , Postoperative Complications/mortality , Acute Disease , Aged , Aged, 80 and over , Anemia/mortality , Cardiopulmonary Bypass/adverse effects , Cardiopulmonary Bypass/statistics & numerical data , Cardiovascular Diseases/epidemiology , Erythrocyte Transfusion/statistics & numerical data , Female , Humans , Length of Stay/statistics & numerical data , Logistic Models , Male , Middle Aged , Predictive Value of Tests , Prognosis , Reoperation/statistics & numerical data , Retrospective Studies , Risk Factors
20.
Biomed Mater ; 3(1): 015008, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18458495

ABSTRACT

In the present study, we studied the involvement of BMP-2 and BMP-7 as homodimers and as a mixture of homodimers in bone regeneration using an engineered bone model. The engineered bone model consisted of a collagen scaffold populated with osteoblasts that acted as a carrier for the BMPs. BMP-2, BMP-7 and a mixture of BMP-2/BMP-7 were used at final concentrations of 10 and 100 ng ml(-1). Osteoblasts seeded onto a collagen scaffold were cultured for 24 h before being stimulated with the BMPs. Four days later, osteoblast adhesion to and growth on the scaffold were assessed. Osteocalcin, IL-6, metalloproteinase (MMP-2 and MMP-9) and protease inhibitor (TIMP-1 and TIMP-2) mRNA and protein levels were measured. Our results showed that the BMP-2, BMP-7 and a mixture of BMP-2/BMP-7 all promoted osteoblast growth on the collagen scaffold, with the mixture of BMP-2/BMP-7 enhancing the most growth. BMP-2 and the mixture of BMP-2/BMP-7 enhanced osteocalcin (an osteoblast differentiation marker) mRNA expression and protein secretion, likely via the IL-6 pathway given that IL-6 secretion was upregulated by BMP-7 and a mixture of BMP-2/BMP-7. BMPs promote extracellular matrix production by inhibiting MMP-2 mRNA and increasing TIMP-1 and TIMP-2 mRNA expressions and protein secretions. BMP-2, BMP-7 and the mixture of BMP-2/BMP-7 could promote bone regeneration via different mechanisms involving IL-6 and MMP inhibitors.


Subject(s)
Bone Morphogenetic Proteins/administration & dosage , Collagen/chemistry , Osteoblasts/physiology , Tissue Engineering/methods , Transforming Growth Factor beta/administration & dosage , Bone Morphogenetic Protein 2 , Bone Morphogenetic Protein 7 , Bone Morphogenetic Proteins/chemistry , Cell Adhesion/drug effects , Cell Culture Techniques/methods , Cell Line , Cell Proliferation/drug effects , Dimerization , Dose-Response Relationship, Drug , Drug Combinations , Humans , Materials Testing , Osteoblasts/cytology , Osteoblasts/drug effects , Transforming Growth Factor beta/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...